Small Animal Hemodialysis with Ultrathin Silicon Nanomembranes

使用超薄硅纳米膜进行小动物血液透析

基本信息

批准号：
8951190
负责人：
James L McGrath
金额：
$ 19.19万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-15 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8951190
关键词：
Accounting Adoption Albumins Animal Model Animals Area Artificial Kidney Biological Blood Blood Pressure Blood flow Caring Cessation of life Companions Computer Simulation Data Development Devices Dialysis patients Dialysis procedure Diet Economics End stage renal failure Frequencies Future Hand Health Health Benefit Heart Rate Height Hemodialysis Home Hemodialysis Home environment Hour In Vitro Incentives Injury Lead Measures Medicare Membrane Metabolic Clearance Rate Microfluidic Microchips Modeling Patients Pilot Projects Plasma Porosity Property Proteins Quality of life Rattus Renal Replacement Therapy Reporting Risk Safety Series Silicon Solutions Surface System Technology Testing Therapeutic Time Translating Treatment Protocols Ultrafiltration Urea Water Weight base beneficiary biomaterial compatibility cost design flexibility health economics improved membrane flux nano novel pressure protein activation public health relevance research study sensor trend

项目摘要

DESCRIPTION (provided by applicant): There are ~430,000 patients with End Stage Renal Disease (ESRD) in the US on hemodialysis (HD) accounting for > 6% of all Medicare spending ($34B). Home hemodialysis (HHD) is both less expensive than in-center dialysis (ICHD) and beneficial to patients because it enables more frequent dialysis. Despite these benefits HHD adoption is low (1.5%) in part because of the complexity and safety concerns associated with patient managed dialysis. This proposal will test the hypothesis that a novel, highly permeable dialysis membrane technology (silicon nanomembranes) can reduce the amount of membrane area required for hemodialysis 100 fold. Such a breakthrough can help drive the adoption of HHD by dramatically changing the format for dialysis by enabling smaller and wearable devices, shorter and more effective dialysis times, and simpler systems. Aim 1 will use bench top studies to establish a preliminary optimum operational conditions (flow rates, membrane properties) that maximize urea clearance while achieving ideal ultrafiltration rates. Aim 2 will use the bench top optimization from Aim 1 as a baseline condition for small animal studies (rats). Rats will be made uremic through diet and hemodialysis experiments with nanomembranes will again identify an optimum condition for urea clearance. Studies will also measure middle weight protein clearance, albumin retention, ultrafiltration and cellular and protein activation. All resuts will be compared directly to results with conventional HD membranes. Our hypothesis will be supported if the membrane surface area required for a therapeutic reduction of urea (KT/V = 1.2) is 100x less for silicon nano membranes than for conventional membranes. The studies are motivated by promising preliminary findings in a small animal model performed under non-optimized conditions.

描述（通过应用程序证明）：在美国的血液透析（HD）中，所有Medicare支出的终末期肾脏疾病（ESRD）（ESRD）（34B $ 34B）都比中心价格低。透析（ICHD），因为它可以使更多的透析（1.5％），部分原因是与托管透析相关的复杂性和安全性问题。血液透析所需的膜面积100倍。从AIM 1作为小型动物研究的AIM 1的最大化，这是最大化的超滤率。如果对硅纳米memrranes的尿素还原所需的膜表面积（KT/V = 1.2）比传统的膜相比，蛋白质的激活比传统的膜少100倍。